OraSure Technologies, Inc.

As of February 25, 2025, OraSure Technologies, Inc. is considered overvalued and risky due to negative financial ratios, including a Price to Book Value of 0.55 and a negative ROE of -6.96%, indicating it is priced higher than its underlying value compared to peers.

As of February 25, 2025, OraSure Technologies, Inc. is considered overvalued and risky, with a negative return on equity and poor stock performance compared to its peers and the S&P 500.

As of June 18, 2025, OraSure Technologies, Inc. exhibits a mildly bearish trend, with daily moving averages and Bollinger Bands indicating bearishness, while mixed signals from MACD and KST suggest caution.

As of March 2022, the management team of OraSure Technologies, Inc. includes Dr. Stephen Tang (CEO), Mr. Michael Celano (Chairman), and several independent directors, ensuring a diverse leadership structure.

OraSure Technologies, Inc. develops and sells oral fluid diagnostic products and specimen collection devices, with a market cap of approximately $210.19 million. As of March 2025, the company reported net sales of $30 million but incurred a net loss of $16 million.

As of Jun 18, OraSure Technologies, Inc. has a market capitalization of 210.19 million, with net sales of 161.63 million and a net profit of -31.95 million over the latest four quarters. The company reported shareholder's funds of 410.34 million and total assets of 479.66 million as of Dec 24.